



DATE: June 17, 2004 SHEET 1 of 2

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

7023US02

10/743,954

APPLICANT

R. Kurukulasuriya et al.

FILING DATE

GROUP

December 23, 2003

1614 1626

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER						ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
NG	A1	5	7	7	6	9	5	4	07/07/98	de Laszlo, et al.	—	—
NG	A2	5	8	8	0	1	3	9	03/09/99	Chang	—	—
NG	A3	6	2	1	8	4	3	1	04/17/2001	Schoen, et al.	—	—

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER						PUBLI-CATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
NG	B1	9	7	1	6	4	4	2	09.05.97	WO	—	—
NG	B2	9	8	2	1	9	5	7	28.05.98	WO	—	—
NG	B3	9	8	2	2	1	0	8	28.05.98	WO	—	—
NG	B4	9	8	2	2	1	0	9	28.05.98	WO	—	—
NG	B5	9	9	0	1	4	2	3	14.01.99	WO	—	—
NG	B6	0	0	3	9	0	8	8	06.07.2000	WO	—	—
NG	B7	0	0	6	9	8	1	0	23.11.2000	WO	—	—
NG	B8	0	2	0	0	6	1	2	03.01.2002	WO	—	—
NG	B9	0	2	4	0	4	4	4	23.05.2002	WO	—	—
NG	B10	0	2	4	0	4	4	5	23.05.2002	WO	—	—
NG	B11	0	2	4	0	4	4	6	23.05.2002	WO	—	—

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

NG	C1	Ahrén, B., & Larsson, H., "Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations", <i>Diabetologia</i> , 44:1998-2003 (2001)
NG	C2	Baron, A. C., et al., "Role of Hyperglucagonemia in Maintenance of Increased Rates of Hepatic Glucose Output in Type II Diabetics", <i>Diabetes</i> , 36:274-283 (1987)
NG	C3	Brand, C. L., et al., "Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose In Conscious, Nondiabetic, and Alloxan-Induced Diabetic Rabbits", <i>Diabetes</i> , 46:1076-1083 (1996)
NG	C4	Brand, C. L., et al., "Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats", <i>Diabetologia</i> , 37:985-993 (1994)
NG	C5	Brand, C. L., et al., <i>American Diabetes Assn Poster Session in San Antonio, TX</i> , pgs. A81 & A428 (2000)
NG	C6	Cascieri, M. A., et al., "Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor", <i>The Journ. of Biol. Chem.</i> 1999, 274:8694-8697 (1999)
✓ NG	C7	Chang, L. L., et al., "Substituted Imidazoles as Glucagon Receptor Antagonists", <i>Bioorganic & Med. Chem. Ltrs.</i> , 11:2549-2553 (2001)
NG	C8	de Feo, P., et al., "Contribution of cortisol to glucose counterregulation in humans", <i>Am. J. Physiol.</i> 257:E35-E42 (1989)
NG	C9	de Laszlo, S. E., et al., "POTENT, ORALLY ABSORBED GLUCAGON RECEPTOR ANTAGONISTS", <i>Bioorganic & Med. Chem. Ltrs.</i> , 9:641-646
NG	C10	DeFronzo, R. A., "Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes", <i>Diabetes Reviews</i> , 5(3):177-269 (1997)

S.O.O

NG	C11	Dinneen, S., et al., "Metabolic Effects of the Nocturnal Rise in Cortisol on Carbohydrate Metabolism in Normal Humans", <i>J. Clin. Invest.</i> , 92:2283-2290 (1993)
NG	C12	Dobbs, R., et al., "Glucagon: Role in the Hyperglycemia of Diabetes Mellitus", <i>Science</i> , 187:544-547 (1975)
NG	C13	Friedman et al., <i>J. Biol. Chem.</i> , 272(50):31475-31481 (1997)
NB	C14	Guillon, J., et al., "Synthesis of new pyrrolo[1,2-a]quinoxalines: potential non-peptide glucagon receptor antagonists", <i>Eur. J. Med. Chem.</i> , 33:293-308 (1998)
NG	C15	Ladouceur, G. H., et al., "4-Phenylpyridine glucagon receptor antagonists: synthetic approaches to the sterically hindered chiral hydroxy group", <i>Tetrahedron Ltrs.</i> , 43:4455-4458 (2002)
NG	C16	Ladouceur, G. H., et al., "Discovery of 5-Hydroxyalkyl-4-phenylpyridines as a New Class of Glucagon Receptor Antagonists", <i>Bioorganic & Med. Chem. Ltrs.</i> , 12:461-464 (2002)
NG	C17	Langley et al., <i>Am. J. Physiol.</i> 259(Regulatory Integrative Comp. Physiol. 28):R539-R544 (1990)
NP	C18	Ling, A., et al., "Human Glucagon Receptor Antagonists Based on Alkylidene Hydrazides", <i>Bioorganic & Med. Chem. Ltrs.</i> , 12:663-666 (2002)
NG	C19	Ling, A., et al., "Identification of Alkylidene Hydrazides as Glucagon Receptor Antagonists", <i>J. Med. Chem.</i> , 44:3141-3149 (2001)
NG	C20	Madsen, P., et al., "Discovery and Structure-Activity Relationship of the First Non-Peptide Competitive Human Glucagon Receptor Antagonists", <i>J. Med. Chem.</i> , 41:5150-5157 (1998)
NG	C21	Magnusson, I., et al., "Increased Rate of Gluconeogenesis in Type II Diabetes Mellitus A 13C Nuclear Magnetic Resonance Study", <i>J. Clin. Invest.</i> , 90:1323-1327 (1992)
NP	C22	Parker, J. C., et al., "Effects of Skyrin, a Receptor-Selective Glucagon Antagonist, in Rat and Human Hepatocytes", <i>Diabetes</i> , 49:2079-2086 (2000)
NG	C23	Petersen K. F. & Sullivan, J. T., "Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans", <i>Diabetologia</i> , 44:2018-2024
NG	C24	Post, S. R., et al., "Mechanism of Action of des-His [Glu ⁹]glucagon amide, a peptide antagonist of the glucagon receptor system", <i>Proc. Natl. Acad. Sci. USA</i> , 90:1662-1666 (1993)
NG	C25	Reaven, G. M., et al., "Documentation of Hyperglucagonemia Throughout the Day in Nonobese and Obese Patients with Noninsulin-Dependent Diabetes Mellitus", <i>J. of Clin. Endocrin. & Metab.</i> , 64:106-110 (1987)
NG	C26	Rizza, R., et al., "Effect of Intermittent Endogenous Hyperglucagonemia on Glucose Homeostasis in Normal and Diabetic Man", <i>J. Clin. Invest.</i> , 63:1119-1123 (1979)
NG	C27	Rooney, D. P., et al., "The Effect of Cortisol on Glucose/Glucose-6-Phosphate Cycle Activity and Insulin Action", <i>J. Clin. Endocrin. & Metabol.</i> , 77:1180-1183 (1994)
NG	C28	Shah, P., et al., "Impact of lack of suppression of glucagon on glucose tolerance in humans", <i>Am. J. Physiol.</i> , 277:E283-E290 (1999)
NG	C29	Shah, P., et al., "Lack of Suppression of Glucagon Contribut4s to Postprandial Hyperglycemia in Subjects with Type 2 Diabetes Mellitus", <i>J. Clin. Endocrinol. & Metabol.</i> , 85:4053-4059 (2000)
NG	C30	Smith, R. A., "Optimization of the 4-Aryl Group of 4-Aryl-pyridine Glucagon Antagonists: Development of an Efficient, Alternative Synthesis", <i>Bioorganic & Medicinal Chem. Ltrs.</i> , 12:1303-1306 (2002)
NG	C31	Terleckyj, I., et al., "The Glucagon Receptor Antagonist ALT 3000 Lowers Fasting Hyperglycemia in Rat Models of Diabetes", <i>Diabetes</i> , 45:220A (1996)
NG	C32	Unger, R. H., & Orci, L., "Glucagon", <i>Joslin's Diabetes Mellitus</i> , Chapt. 9:163-176 (1994)
NG	C33	Unger, R. H., "Glucagon physiology and pathophysiology in the light of new advances", <i>Diabetologia</i> , 28:574-578 (1985)
NP	C34	Unger, R. H., "Role of Glucagon in the Pathogenesis of Diabetes: The Status of the Controversy", <i>Metabolism</i> , 27(11):1691-1709 (1978)
NG	C35	Unger, R. H., "THE ESSENTIAL ROLE OF GLUCAGON IN THE PATHOGENESIS OF DIABETES MELLITUS", <i>Lancet</i> , 1:14-16 (1975)
NG	C36	Unson, C. G., et al., "Biological Activities of des-His [Glu ⁹]Glucagon Amide, a Glucagon Antagonist", <i>Peptides</i> , 10:1171177 (1989)
NG	C37	Unson, C. G., et al., "Multiple-site Replacement Analogs of Glucagon", <i>Journ. of Biol. Chem.</i> , 269(17):12548-12551 (1994)
NG	C38	Walker et al., <i>Am. J. Physiol.</i> 262(Endocrinol. Metab. 25):E110-E117 (1992)
NG	C39	Wright, L. M., et al., "Structure of Fab hGR-2 F6, a competitive antagonist of the glucagon receptor", <i>Acta Cryst.</i> , D56:573-580 (2000)
NG	C40	Zieze, B. Y., et al., "[des-His ¹ -des-Phe ⁹ -Glu ⁹]GLUCAGON-AMIDE: A NEWLY DESIGNED "PURE" GLUCAGON ANTAGONIST", <i>Bioorganic & Medic. Chem. Ltrs.</i> , 5(16):1849-1852 (1995)

EXAMINER

DATE CONSIDERED

5/16/05

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Aveed
Not

Q-0-0